在转移性前列腺癌中使用白金化疗:有哪些可能性?
Martina Catalano1,2, Andrea Lapucci3, Stefania Nobili4
1Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, 50139, Florence, Italy. martina.catalano@unifi.it.
Cancer chemotherapy and pharmacology
|November 7, 2023
概括
化疗和PARP抑制剂对转移性前列腺癌与DNA修复基因突变有希望. 需要进一步的研究来优化治疗序列和管理潜在的毒性.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 转移性前列腺癌 (mPC) 是一个重大的全球健康挑战.
- 抗雄激素剥夺疗法是标准的,但对于转移性割抵抗性前列腺癌 (mCRPC) 新疗法至关重要.
- 像BRCA1/2这样的DNA修复基因的突变在mCRPC中很常见,增加了对化疗和PARP抑制剂的敏感性.
研究的目的:
- 审查基化疗在前列腺癌中的作用,特别是在具有同源复合修复 (HRR) 突变的患者中.
- 探索将化合物与PARP抑制剂结合在一起的协同潜力.
- 讨论最佳的治疗序列和潜在的挑战.
主要方法:
- 文献综述侧重于基于的化疗和mCRPC中的PARP抑制剂.
- 对涉及HRR基因变异患者的研究进行分析.
- 讨论治疗策略,测序和毒性.
主要成果:
- 基于的化疗,特别是使用税,在mCRPC中显示出有效性.
- HRR突变的mCRPC患者对化合物的敏感性增加.
- 将化疗与PARP抑制剂结合起来是一个有前途的策略.
结论:
- 基于的化疗和PARP抑制剂为HRR突变的mCRPC患者提供了一种新的治疗途径.
- 交叉耐药性/毒性的最佳测序和管理需要通过前性随机试验进行进一步的调查.
- 这种方法有可能改善特定mCRPC子组的结果.
更多相关视频
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.1K
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:30Metastasis
5.6K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K